Cellectis (CLLS) Current Leases (2016 - 2026)
Cellectis (CLLS) posted quarterly Current Leases of $6.3 million for Q1 2026, down 20.44% year-over-year from $7.9 million in Q1 2025, and down 18.78% quarter-over-quarter from $7.7 million in Q4 2025.
Cellectis (CLLS) Current Leases (2016 - 2026) Analysis & Trends
Cellectis' Current Leases history runs 11 years deep, the most recent figure standing at $6.3 million for Q1 2026.
- In Q1 2026, Current Leases fell 20.44% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (down 20.44% YoY), while the FY2025 annual figure was $7.7 million, down 8.16% from the prior year.
- Current Leases for Q1 2026 stood at $6.3 million, down from $7.7 million in the prior quarter.
- The five-year high for Current Leases was $8.5 million in Q3 2024, with the low at $6.3 million in Q1 2026.
- The 5-year median for Current Leases is $8.2 million (2023), against an average of $8.0 million.
- The sharpest annual moves came in 2022 and 2026: Current Leases advanced 20.37% in 2022, then dropped 20.44% in 2026.
- Cellectis' Current Leases stood at $7.9 million in 2022, then grew by 8.0% to $8.5 million in 2023, then dropped by 1.38% to $8.4 million in 2024, then slipped by 8.16% to $7.7 million in 2025, then fell by 18.78% to $6.3 million in 2026.
- Business Quant data shows CLLS's Current Leases at $6.3 million in Q1 2026, $7.7 million in Q4 2025, and $8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 6.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | 7.70 Mn |
| Sep 30, 2025 | 8.33 Mn |
| Jun 30, 2025 | 7.48 Mn |
| Mar 31, 2025 | 7.86 Mn |
| Dec 31, 2024 | 8.39 Mn |
| Sep 30, 2024 | 8.51 Mn |
| Jun 30, 2024 | 8.36 Mn |
| Mar 31, 2024 | 8.40 Mn |
| Dec 31, 2023 | 8.50 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 8.27 Mn |
| Mar 31, 2023 | 8.18 Mn |
| Dec 31, 2022 | 7.87 Mn |
| Sep 30, 2022 | 7.97 Mn |
| Jun 30, 2022 | 8.09 Mn |
| Mar 31, 2022 | 8.41 Mn |
| Dec 31, 2021 | 8.33 Mn |
| Sep 30, 2021 | 8.08 Mn |
| Jun 30, 2021 | 7.69 Mn |